Navegando por Autor "Vieira, Joseli Lannes"

Filtrar resultados informando as primeiras letras
Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura Disponível
    Item
    ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of chagas’ disease.
    (2023) Castro, Júlia Teixeira de; Brito, Rory Cristiane Fortes de; Souza, Natália Satchiko Hojo de; Azevedo, Bárbara Ribeiro Batista Vaz de; Castro, Natália Salazar de; Ferreira, Camila Pontes; Giusta, Caroline Junqueira; Fernandes, Ana Paula Salles Moura; Vasconcellos, José Ronnie Carvalho de; Cardoso, Jamille Mirelle de Oliveira; Soares, Rodrigo Dian de Oliveira Aguiar; Vieira, Paula Melo de Abreu; Carneiro, Cláudia Martins; Valiate, Bruno Vinícius Santos; Toledo, Cristiane; Salazar, Andres M.; Caballero, Otávia; Vieira, Joseli Lannes; Teixeira, Santuza Maria Ribeiro; Reis, Alexandre Barbosa; Gazzinelli, Ricardo Tostes
    Immunization with the Amastigote Surface Protein-2 (ASP-2) and Trans-sialidase (TS) antigens either in the form of recombinant protein, encoded in plasmids or human adenovirus 5 (hAd5) confers robust protection against various lineages of Trypanosoma cruzi. Herein we generated a chimeric protein containing the most immunogenic regions for T and B cells from TS and ASP-2 (TRASP) and evaluated its immunogenicity in comparison with our standard protocol of heterologous prime-boost using plasmids and hAd5. Mice immunized with TRASP protein associated to Poly-ICLC (Hiltonol) were highly resistant to challenge with T. cruzi, showing a large decrease in tissue parasitism, parasitemia and no lethality. This protection lasted for at least 3 months after the last boost of immunization, being equivalent to the protection induced by DNA/hAd5 protocol. TRASP induced high levels of T. cruzispecific antibodies and IFNγ-producing T cells and protection was primarily mediated by CD8+ T cells and IFN-γ. We also evaluated the toxicity, immunogenicity, and efficacy of TRASP and DNA/hAd5 formulations in dogs. Mild collateral effects were detected at the site of vaccine inoculation. While the chimeric protein associated with Poly-ICLC induced high levels of antibodies and CD4+ T cell responses, the DNA/hAd5 induced no antibodies, but a strong CD8+ T cell response. Immunization with either vaccine protected dogs against challenge with T. cruzi. Despite the similar efficacy, we conclude that moving ahead with TRASP together with Hiltonol is advantageous over the DNA/hAd5 vaccine due to pre-existing immunity to the adenovirus vector, as well as the cost-benefit for development and large-scale production.
  • Nenhuma Miniatura Disponível
    Item
    In vitro and in vivo experimental models for drug screening and development for Chagas disease.
    (2010) Romanha, Alvaro José; Castro, Solange Lisboa de; Soeiro, Maria de Nazaré Correia; Vieira, Joseli Lannes; Ribeiro, Isabela; Silva, André Talvani Pedrosa da; Bourdin, Bernadette; Blum, Bethania; Olivieri, Bianca; Zani, Carlos Leomar; Spadafora, Carmenza; Chiari, Egler; Chatelain, Eric; Chaves, Gabriela; Calzada, José Eduardo; Bustamante, Juan Manuel; Freitas Junior, Lucio Holanda Godim de; Romero, Luz I.; Bahia, Maria Terezinha; Lotrowska, Michel; Soares, Milena Botelho Pereira; Andrade, Sonia Gumes; Lotrowska, Tanya; Degrave, Wim; Andrade, Zilton de Araújo
    Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.